{"DataElement":{"publicId":"6663747","version":"1","preferredName":"Stage I, II, or III Prostate Adenocarcinoma Hormone Therapy Received or Expected Eligibility Determination Indicator","preferredDefinition":"Yes No indicator to specify whether the patient has stage I, II, or II prostate adenocarcinoma and has received or is expected to receive hormonal therapy","longName":"6662752v1.0:3506068v1.0","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"6662752","version":"1","preferredName":"Stage I, II, or III Prostate Adenocarcinoma Hormone Therapy Received or Expected Eligibility Determination","preferredDefinition":"An adenocarcinoma arising from the prostate gland.  It is one of the most common malignant tumors afflicting men.  The majority of adenocarcinomas arise in the peripheral zone and a minority occurs in the central or the transitional zone of the prostate gland.  Grading of prostatic adenocarcinoma predicts disease progression and correlates with survival.  Several grading systems have been proposed, of which the Gleason system is the most commonly used.  Gleason sums of 2 to 4 represent well-differentiated disease, 5 to 7 moderately differentiated disease and 8 to 10 poorly differentiated disease.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic adenocarcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease._The act of determining if a subject is suitable for enrollment in a study according specific protocol criteria and procedures._Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level._Coming into possession of or acting as the receptacle or recipient of an item conveyed by an intermediary to the intended destination, from a sender._Considered likely or probable; anticipated._Invasive cancer confined to the original anatomic site of growth without lymph node involvement._Invasive cancer more extensive than stage I, usually involving local lymph nodes without spread to distant anatomic sites._Locally advanced cancer that has spread to nearby organs but not to distant anatomic sites.","longName":"6662749v1.0:6662750v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"6662749","version":"1","preferredName":"Stage I Stage II Stage III Prostate Adenocarcinoma","preferredDefinition":"Invasive cancer confined to the original anatomic site of growth without lymph node involvement.:Invasive cancer more extensive than stage I, usually involving local lymph nodes without spread to distant anatomic sites.:Locally advanced cancer that has spread to nearby organs but not to distant anatomic sites.:An adenocarcinoma arising from the prostate gland.  It is one of the most common malignant tumors afflicting men.  The majority of adenocarcinomas arise in the peripheral zone and a minority occurs in the central or the transitional zone of the prostate gland.  Grading of prostatic adenocarcinoma predicts disease progression and correlates with survival.  Several grading systems have been proposed, of which the Gleason system is the most commonly used.  Gleason sums of 2 to 4 represent well-differentiated disease, 5 to 7 moderately differentiated disease and 8 to 10 poorly differentiated disease.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic adenocarcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","longName":"C27966:C28054:C27970:C2919","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage I","conceptCode":"C27966","definition":"Invasive cancer confined to the original anatomic site of growth without lymph node involvement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Stage II","conceptCode":"C28054","definition":"Invasive cancer more extensive than stage I, usually involving local lymph nodes without spread to distant anatomic sites.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Stage III","conceptCode":"C27970","definition":"Locally advanced cancer that has spread to nearby organs but not to distant anatomic sites.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Prostate Adenocarcinoma","conceptCode":"C2919","definition":"An adenocarcinoma arising from the prostate gland.  It is one of the most common malignant tumors afflicting men.  The majority of adenocarcinomas arise in the peripheral zone and a minority occurs in the central or the transitional zone of the prostate gland.  Grading of prostatic adenocarcinoma predicts disease progression and correlates with survival.  Several grading systems have been proposed, of which the Gleason system is the most commonly used.  Gleason sums of 2 to 4 represent well-differentiated disease, 5 to 7 moderately differentiated disease and 8 to 10 poorly differentiated disease.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic adenocarcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83829135-E002-66AA-E053-F662850A5B2E","latestVersionIndicator":"Yes","beginDate":"2019-03-07","endDate":null,"createdBy":"RODGERSC","dateCreated":"2019-03-07","modifiedBy":"ONEDATA","dateModified":"2019-03-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6662750","version":"1","preferredName":"Hormone Therapy Receive Expected Eligibility Determination","preferredDefinition":"Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level.:To take, accept, or get something offered.:Considered likely or probable; anticipated.:The act of determining if a subject is suitable for enrollment in a study according specific protocol criteria and procedures.","longName":"C15445:C25639:C25501:C25171","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hormone Therapy","conceptCode":"C15445","definition":"Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Receive","conceptCode":"C25639","definition":"To take, accept, or get something offered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Expected","conceptCode":"C25501","definition":"Considered likely or probable; anticipated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Eligibility Determination","conceptCode":"C25171","definition":"The act of determining if a subject is suitable for enrollment in a study according specific protocol criteria and procedures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83829135-E015-66AA-E053-F662850A5B2E","latestVersionIndicator":"Yes","beginDate":"2019-03-07","endDate":null,"createdBy":"RODGERSC","dateCreated":"2019-03-07","modifiedBy":"ONEDATA","dateModified":"2019-03-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435018","version":"1","preferredName":"Clinical or Research Activity","preferredDefinition":"Any specific activity undertaken during the course of a clinical study or research protocol.","longName":"C16203","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741AE5B-831E-25C7-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83829135-E026-66AA-E053-F662850A5B2E","latestVersionIndicator":"Yes","beginDate":"2019-03-07","endDate":null,"createdBy":"RODGERSC","dateCreated":"2019-03-07","modifiedBy":"RODGERSC","dateModified":"2019-03-08","changeDescription":"created for WFBCCC 3/7/19 cmr","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"6147165","version":"1","longName":"Wake Forest Baptist Medical Center","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6147167","version":"1","longName":"WFB","context":"NCIP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Male diagnosed with adenocarc","type":"Preferred Question Text","description":"Male diagnosed with adenocarcinoma of the prostate, stage I, II, or III. Patient may have already received hormonal therapy or expect to receive hormonal therapy as treatment for adenocarcinoma of the prostate","url":null,"context":"NCIP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"839B163A-244A-253C-E053-F662850AECFB","latestVersionIndicator":"Yes","beginDate":"2019-03-08","endDate":null,"createdBy":"RODGERSC","dateCreated":"2019-03-08","modifiedBy":"MAESKEB","dateModified":"2021-03-11","changeDescription":"created for WFBCCC 3/8/19 cmr","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}